Evolv director exercises options and sells shares

Q: Was Michael Ellenbogen’s Evolv Technologies (EVLV) stock sale pre-planned?

Yes. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan entered into on June 12, 2025. Such plans pre-schedule trades, indicating the timing of this sale was arranged in advance rather than decided spontaneously.

Q: At what prices were Michael Ellenbogen’s Evolv Technologies (EVLV) shares sold?

The Form 4 reports a weighted average sale price of $6.32 per share. A footnote explains the 80,745 shares were sold in multiple trades at prices ranging from $6.27 to $6.39 per share on the transaction date.

Q: What were the terms of the Evolv Technologies (EVLV) stock options exercised by Michael Ellenbogen?

Ellenbogen exercised 80,745 stock options with an exercise price of $0.24 per share. A footnote states this option vested 25% on January 31, 2018, with the remaining portion vesting in 36 equal monthly installments thereafter until fully vested.

Evolv Technologies Holdings director Michael Ellenbogen exercised stock options and sold shares in a routine, pre-planned transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Evolv Technologies Holdings director Michael Ellenbogen exercised stock options and sold shares in a routine, pre-planned transaction. He exercised 80,745 stock options at an exercise price of $0.24 per share, receiving the same number of Class A Common shares.

On the same day, he sold 80,745 Class A Common shares at a weighted average price of $6.32 per share under a Rule 10b5-1 trading plan. After these transactions, he directly owned 2,083,961 Class A Common shares and indirectly held 151,135 shares through the Family Horizon Trust.

Insider Trade Summary 10b5-1

Exercise and Sale: 80,745 shares ($491K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Ellenbogen Michael

Role Director

Sold 80,745 shs ($510K)

Approx. gross sale proceeds $510K

Approx. exercise cost $19K

Approx. pre-tax spread $491K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	80,745	$0.00	$0.00
Exercise	Class A Common Stock	80,745	$0.24	$19K
Sale	Class A Common Stock	80,745	$6.32	$510K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 1,139,249 contracts (Direct); Class A Common Stock — 2,083,961 shares (Direct); Class A Common Stock — 151,135 shares (Indirect, Held by Family Horizon Trust)

Footnotes (3)

F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 12, 2025.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.27 to $6.39. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The option vested and become exercisable as to 25% on January 31, 2018 and vested in 36 equal monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Michael Ellenbogen report at Evolv Technologies (EVLV)?

Michael Ellenbogen reported exercising 80,745 stock options at an exercise price of $0.24 and selling 80,745 Class A Common shares at a weighted average price of $6.32 per share, as disclosed in a Form 4 insider trading report.

Was Michael Ellenbogen’s Evolv Technologies (EVLV) stock sale pre-planned?

Yes. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan entered into on June 12, 2025. Such plans pre-schedule trades, indicating the timing of this sale was arranged in advance rather than decided spontaneously.

How many Evolv Technologies (EVLV) shares does Michael Ellenbogen own after this Form 4?

After the reported transactions, Michael Ellenbogen directly owned 2,083,961 Evolv Technologies Class A Common shares and indirectly held another 151,135 shares through the Family Horizon Trust, as shown in the ownership totals following the transactions.

At what prices were Michael Ellenbogen’s Evolv Technologies (EVLV) shares sold?

The Form 4 reports a weighted average sale price of $6.32 per share. A footnote explains the 80,745 shares were sold in multiple trades at prices ranging from $6.27 to $6.39 per share on the transaction date.

What were the terms of the Evolv Technologies (EVLV) stock options exercised by Michael Ellenbogen?

Ellenbogen exercised 80,745 stock options with an exercise price of $0.24 per share. A footnote states this option vested 25% on January 31, 2018, with the remaining portion vesting in 36 equal monthly installments thereafter until fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/17/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ellenbogen Michael

(Last)

(First)

(Middle)

C/O EVOLV TECHNOLOGIES, INC.

500 TOTTEN POND ROAD, 4TH FLOOR

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evolv Technologies Holdings, Inc. [ EVLV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	04/15/2026		M		80,745	A	$0.24	2,164,706	D
Class A Common Stock	04/15/2026		S⁽¹⁾		80,745	D	$6.32⁽²⁾	2,083,961	D
Class A Common Stock								151,135	I	Held by Family Horizon Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.24	04/15/2026		M			80,745	⁽³⁾	09/13/2027	Class A Common Stock	80,745	$0	1,139,249	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 12, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.27 to $6.39. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The option vested and become exercisable as to 25% on January 31, 2018 and vested in 36 equal monthly installments thereafter.

Remarks:

	/s/ Rachel Roy, Attorney-in-fact for Michael Ellenbogen	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR